Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)

TL;DR

This study found that larger tumor size at the start of treatment is linked to worse survival in rare cancer patients treated with immunotherapy.

Contribution

The study is the first to show that baseline tumor burden correlates with survival outcomes in rare cancers treated with dual immune checkpoint inhibitors.

Findings

Larger baseline tumor burden correlated with shorter overall survival but not progression-free survival.

Tumor burden was independently associated with survival in multivariable analysis.

Tumor burden was not predictive of tumor regression after immunotherapy.

Abstract

It has been suggested that baseline tumor burden may correlate with immune checkpoint inhibitor (ICI) outcome for individual tumor types in which ICIs are standardly used. The authors investigated whether pretreatment tumor burden correlates with overall survival (OS), progression‐free survival (PFS), and tumor regression among patients who had rare cancers treated with dual ICIs.

Southwest Oncology Group study S1609 was a phase 2, National Cancer Institute/Southwest Oncology Group basket study (>1000 sites) evaluating nivolumab plus ipilimumab in 53 cohorts of patients who had rare/ultrarare malignancies (ClinicalTrials.gov identifier NCT02834013). Overall, 722 patients were included in this secondary analysis, all of whom had measurable disease (Response Evaluation Criteria in Solid Tumors, version 1.1). Baseline tumor burden, defined as the sum of the greatest dimensions of target lesions at study registration, was analyzed based on quartiles observed in the data. The number of target lesions was also considered a secondary tumor burden measure. End points included OS and PFS.

Larger baseline tumor burden correlated with shorter OS, but not PFS (multivariable analysis). Higher baseline tumor burden quartiles had only a weak negative association with any tumor regression at first scan (Fisher exact test, p = .09), and multivariable analyses further indicated that both tumor burden and any tumor regression at first posttreatment scan were independently associated with OS in multivariable analysis (comparing a baseline tumor size ≥12.9 cm vs. 1.0–4.8 cm; hazard ratio, 1.64; 95% confidence interval, 1.02–1.72; p = .032), but there was no evidence of an interaction between tumor burden and any tumor regression at the first scan (p for interaction > .65).

Larger baseline tumor burden was associated with worse OS, but not PFS, and was not predictive of tumor regression after dual ICI therapy in a large cohort with rare cancer types.

Higher tumor burden, as measured by standard‐of‐care imaging, has been implicated as a marker for poor outcome after immune checkpoint inhibitor therapy for individual common cancer types in which immune checkpoint blockade is routinely used. This secondary analysis of 722 evaluable patients enrolled in a large, prospective, National Cancer Institute, multibasket trial evaluating nivolumab plus ipilimumab demonstrates that larger baseline tumor burden, as assessed by tumor size or by the number of target lesions, correlates significantly and independently with shorter survival but is not similarly associated with progression‐free survival or tumor regression.

Figures